Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04601012
Recruitment Status : Completed
First Posted : October 23, 2020
Last Update Posted : January 19, 2021
Sponsor:
Information provided by (Responsible Party):
Gilda Cennamo, Federico II University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that have been affected by COVID-19.

Condition or disease Intervention/treatment
Covid19 Diagnostic Test: Optical coherence tomography angiography

Detailed Description:

To investigate the potential role of optical coherence tomography angiography in identifying the changes in retinal vessel density in patients that have been affected by COVID-19.

The optical coherence tomography angiography represents a noninvasive diagnostic technique that allows a detailed analysis of retinal vascular features.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Optical Coherence Tomography Angiography in Patients Affected by SARS-CoV-2 Infection: a Pilot Study
Actual Study Start Date : September 20, 2020
Actual Primary Completion Date : October 20, 2020
Actual Study Completion Date : October 22, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients with COVID19
The patients with previous diagnosis of COVID19
 Diagnostic Test: Optical coherence tomography angiography
Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
Control subjects
Healthy subjects without actual and previous ocular diseases
 Diagnostic Test: Optical coherence tomography angiography
Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The measurements of retinal features in patients with previous diagnosis of COVID19, using optical coherence tomography angiography. [ Time Frame: one month ]
    The parameter analyzed by optical coherence tomography angiography was: retinal vessel density


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The participans were older than 18 years with previous diagnosis of COVID-19. They did not present other ophthalmological diseases.
Criteria

Inclusion Criteria:

  • age older than 18 years
  • diagnosis of previous COVID-19
  • absence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
  • absence of significant lens opacities, low-quality OCT and OCT-A images.

Exclusion Criteria:

  • age younger than 18 years
  • absence of previous diagnosis of COVID-19
  • presence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
  • presence of significant lens opacities, low-quality OCT and OCT-A images.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04601012


Locations
Layout table for location information
Italy
University of Naples "Federico II"
Naples, Italy, 80100
Sponsors and Collaborators
Federico II University
Investigators
Layout table for investigator information
Principal Investigator: Gilda Cennamo Federico II University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Gilda Cennamo, Principal Investigator, Federico II University
ClinicalTrials.gov Identifier: NCT04601012    
Other Study ID Numbers: 2020/03
First Posted: October 23, 2020    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Infections
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases